Registered title, quoted from ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07612891, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).
Inclusion criterion 3
Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
Inclusion criterion 4
Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
Exclusion criterion 3
Has undergone major surgery within 28 days prior to the first dose of study drug.
Exclusion criterion 4
Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
Exclusion criterion 6
Have received prior CDK2 inhibitors.
Exclusion criterion 16
ECOG performance status 0-1.
Inclusion criterion 7
Have RECIST 1.1-defined measurable lesions.
Inclusion criterion 5
Confirmed infection with HIV, HBV or HCV.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07612891, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Written informed consent obtained.
- Adult patients aged ≥ 18 years.
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).
- Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
- Have RECIST 1.1-defined measurable lesions.
- Has a life expectancy of > 3 months.
- ECOG performance status 0-1.
- Adequate marrow, liver and kidney function.
- Meet the study's specified contraceptive requirements.
Exclusion Criteria:
- Have a second primary malignancy.
- Patients with primary CNS tumors or CNS metastases with prior local treatment failure.
- Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
- Has undergone major surgery within 28 days prior to the first dose of study drug.
- Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.
- Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
- Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
- Have protocol-defined clinically significant cardiovascular diseases.
- Prolonged QTcF interval.
- Have any medical conditions likely to impair digestion and absorption of the investigational product.
- Patients with poorly managed blood glucose levels and blood pressure.
- Clinically significant abnormal serum potassium or sodium as judged by the investigator.
- Have experienced a severe concurrent infection 14 days prior to the first dose of study drug.
- Confirmed infection with HIV, HBV or HCV.
- Are currently receiving any other investigation agent.
- Have received prior CDK2 inhibitors.
- Patients with known hypersensitivity to the study drug or any of its components.
- History of allogenic tissue or solid organ transplant.
- Are unwilling or unable to comply with procedures required in this protocol.
- Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.
Quoted from ClinicalTrials.gov, NCT07612891, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07612891, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.